Notably, ROS1 mutation served as a favorable predictor for ICI therapy but not a prognostic factor in melanoma, whereas ROS1 fusion and wild-type patients derived limited benefits from ICI therapy, potentially attributed to the relatively elevated tumor antigenicity and genomic instability in ROS1 mutated patients. Here, ROS1 is linked to neoplasm.